25

2020-11

Kintor Pharmaceutical’s SMO Antagonist Obtains Approval of Clinical Trial from FDA

真人直营投注网站 announced that its SMO antagonist GT1708F was approved by the US Food and Drug Administration for clinical trials, and the treatment of basal cell carcinoma will be commenced.

24

2020-11

Kintor Pharmaceutical’s Suzhou Industrialisation Base Granted Approval of Pharmaceutical Production License

真人直营投注网站 announced that the Company’s Suzhou Industrialisation Base was granted the Pharmaceutical Production License issued by Jiangsu Medical Products Administration.

29

2020-10

Kintor Pharmaceutical's COVID-19 Clinical Trials for Proxalutamide to expand Patient Enrolment

真人直营投注网站 is delighted to announced that the clinical trial of anti-androgen treatment Proxalutamide for the novel coronavirus disease (COVID-19) has reached the initial target of 381 patients enrolment on 25 October 2020.

27

2020-10

Kintor Pharmaceutical Selected as the Excellent Case of Advanced Enterprises in 2020 Science and Technology Innovation by People.cn

Kintor Pharmaceutical has been successfully selected as the excellent case of the advanced enterprises in 2020 science and technology Innovation of the People.cn upon provision of comments and recommendations by experts.

16

2020-10

Strategic Cooperation Agreement on Biological Drug Development between Kintor Pharmaceutical and Pumis

On 16 October 2020, 真人直营投注网站 (Stock code: 9939, “Kintor Pharmaceutical”) announced that it has entered into a strategic cooperation agreement on biological drug development with Pumis Pharmaceutical Co., Ltd (“Pumis”).

30

2020-09

Kintor Pharmaceutical Signs Strategic Cooperation Agreement with MabPlex

On 30 September 2020, 真人直营投注网站 announced that Kintor Pharmaceutical entered into a strategic cooperation agreement with MabPlex International Ltd. , pursuant to which both parties will carry out all-round cooperation on the research and development and production in biological macromolecular drugs.

< 1...161718...22 > proceed page

Kintor